Drugs that contain Plecanatide

1. Drug name - TRULANCE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7799897 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jun, 2022

(3 months ago)

US7041786 SALIX Guanylate cyclase receptor agonists for the treatment of tissue inflammation and carcinogenesis
Jan, 2028

(5 years from now)

US10011637 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same
Jun, 2034

(11 years from now)

CN103641892B SALIX Guanylate Cyclase Receptor Agonist For Treating Tissue Inflammation And Cancer
Mar, 2022

(6 months ago)

CN102643333B SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

CN102643333A SALIX Guanylate Cyclase Receptor Stimulant For Treating Tissue Inflammation And Canceration
Mar, 2022

(6 months ago)

CN103641892A SALIX For Treating Tissue Inflammation And Cancer Of Guanylate Cyclase Receptor Agonist
Mar, 2022

(6 months ago)

CN105764916B SALIX A Hyperpure Agonist Of Guanylate Cyclase C, Preparation And Use Method Of The Agonist
Jun, 2034

(11 years from now)

CN105764916A SALIX A Super-Pure Agonist Of Guanylate Cyclase C, Preparation And Using Method Of The Agonist
Jun, 2034

(11 years from now)

EP2103624B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2301952A2 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2944648B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation
Mar, 2022

(6 months ago)

EP2301952B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2103624A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP2944648A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Organ Inflammation
Mar, 2022

(6 months ago)

EP2301952A3 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224B1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224A4 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224A1 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

EP1379224B2 SALIX Guanylate Cyclase Receptor Agonists For The Treatment Of Tissue Inflammation And Carcinogenesis
Mar, 2022

(6 months ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9919024 SALIX Formulations of guanylate cyclase C agonists and methods of use Sep, 2031

(8 years from now)

US9610321 SALIX Formulations of guanylate cyclase C agonists and methods of use Sep, 2031

(8 years from now)

US9925231 SALIX Formulations of guanylate cyclase C agonists and methods of use Sep, 2031

(8 years from now)

US9616097 SALIX Formulations of guanylate cyclase C agonists and methods of use Aug, 2032

(9 years from now)

US11142549 SALIX Ultra-pure agonists of guanylate cyclase C, method of making and using same Jun, 2034

(11 years from now)

Treatment: Irritable bowel syndrome with constipation; chronic idiopathic constipation; Chronic idiopathic constipation; irritable bowel syndrome with constipation

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
3MG TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.